Since the discovery of glucocorticoids, we have had a single strategy for manipulating the immune system in cases of destructive diseases mediated by uncontrolled immune responses. However, long-term use of immunosuppressive drugs can lead to the threat of opportunistic infections and malignancies. As we learn more about regulatory subsets of T lymphocytes and their cytokine profiles, the thrust has been on developing new ligands that ultimately give us more site-specific control. Our group has developed a patented mixture of plant sterols and sterolins that has anti-inflammatory properties and profound immune modulating effects on subsets of CD4+ T cells. We have tested this mixture in several clinical entities and we believe that it has wide applications in reverting immune abnormalities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s1359-6446(02)02343-7 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!